Symic Bio raises $30mm in Series B round

Symic Biomedical Inc. (therapeutics focused on matrix biology) raised $30mm in its Series B financing round that included participation from all existing major investors along with new investor HEDA Ventures. The company has raised over $73mm since its inception through a seed round, a two tranche series A round and the B round. Symic will use the proceeds from the financing to help fund a planned Phase III trial of clinical program SB030 for the prevention of peripheral vein graft failure and to support development of SB061 for pain management and disease modification in treating osteoarthritis of the knee.